glp-1/glucagon dual receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research LY3437943, a novel triple glucagon,

Brands have been endlessly inventive in creating new consumption occasions and products that satisfy our need for a quick pick-up

Danuglipron Danuglipron is a small-molecule GLP-1 receptor agonist, formerly under development by Pfizer [1] that, in an oral formulation, was under investigation as a therapy for diabetes mellitus

North America registered dominance in the market by capturing a 60% share in 2025

While some patients report anxiety on tirzepatide , it is far less common and typically related to the adjustment period rather than a direct pharmacological effect

What is the FDA-approved use of Zepbound

24 This opens the door to exploring these novel compounds as potential therapeutic agents in a broader range of conditions